These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23963862)

  • 1. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.
    McWhinney-Glass S; Winham SJ; Hertz DL; Yen Revollo J; Paul J; He Y; Brown R; Motsinger-Reif AA; McLeod HL;
    Clin Cancer Res; 2013 Oct; 19(20):5769-76. PubMed ID: 23963862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers.
    Zwimpfer TA; Scherer K; Schötzau A; Heinzelmann-Schwarz V; Hartmann K; Vetter M; Montavon C
    Cancer Med; 2024 Jan; 13(1):e6840. PubMed ID: 38140783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).
    Yoshino K; Kamiura S; Yokoi T; Nakae R; Fujita M; Takemura M; Adachi K; Wakimoto A; Nishizaki T; Shiki Y; Tsutsui T; Kanda Y; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Sawada K; Tomimatsu T; Kimura T
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1239-1247. PubMed ID: 29080971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.
    Du XL; Parikh RC; Lairson DR; Giordano SH; Cen P
    Med Oncol; 2013 Mar; 30(1):440. PubMed ID: 23307252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
    JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance of clinical symptoms and electrophysiologic findings in taxane plus platinum-induced neuropathy.
    Pan Y; Kao MS
    Int J Gynecol Cancer; 2007; 17(2):394-7. PubMed ID: 17362318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
    Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cervical non-squamous carcinoma: an effective combination chemotherapy of taxane, anthracycline and platinum for advanced or recurrent cases.
    Kimura T; Miyatake T; Ueda Y; Ohta Y; Enomoto T; Kimura T; Kamiura S
    Eur J Obstet Gynecol Reprod Biol; 2012 Oct; 164(2):200-4. PubMed ID: 22770633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors.
    Thomaier L; Darst BF; Jewett P; Hoffmann C; Brown K; Makaram A; Blaes A; Argenta P; Teoh D; Vogel RI
    Gynecol Oncol; 2021 Dec; 163(3):578-582. PubMed ID: 34674889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial.
    He YJ; Winham SJ; Hoskins JM; Glass S; Paul J; Brown R; Motsinger-Reif A; McLeod HL
    Pharmacogenomics J; 2016 Jun; 16(3):243-8. PubMed ID: 26194361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.
    Su Y; Huang J; Wang S; Unger JM; Arias-Fuenzalida J; Shi Y; Li J; Gao Y; Shi W; Wang X; Peng R; Xu F; An X; Xue C; Xia W; Hong R; Zhong Y; Lin Y; Huang H; Zhang A; Zhang L; Cai L; Zhang J; Yuan Z
    J Natl Cancer Inst; 2020 Jan; 112(1):55-62. PubMed ID: 31093677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.
    De Iuliis F; Salerno G; Taglieri L; Scarpa S
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):679-90. PubMed ID: 26198313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
    Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
    Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.
    Abraham JE; Guo Q; Dorling L; Tyrer J; Ingle S; Hardy R; Vallier AL; Hiller L; Burns R; Jones L; Bowden SJ; Dunn JA; Poole CJ; Caldas C; Pharoah PP; Earl HM
    Clin Cancer Res; 2014 May; 20(9):2466-75. PubMed ID: 24599932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients.
    Johnson C; Pankratz VS; Velazquez AI; Aakre JA; Loprinzi CL; Staff NP; Windebank AJ; Yang P
    J Neurol Sci; 2015 Feb; 349(1-2):124-8. PubMed ID: 25586538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study.
    Niu N; Schaid DJ; Abo RP; Kalari K; Fridley BL; Feng Q; Jenkins G; Batzler A; Brisbin AG; Cunningham JM; Li L; Sun Z; Yang P; Wang L
    BMC Cancer; 2012 Sep; 12():422. PubMed ID: 23006423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature.
    Cardonick E; Bhat A; Gilmandyar D; Somer R
    Ann Oncol; 2012 Dec; 23(12):3016-3023. PubMed ID: 22875836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
    Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
    Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies.
    Wang T; Yu J; Liu M; Chen Y; Zhu C; Lu L; Wang M; Min L; Liu X; Zhang X; Gubat JA; Chen Y
    Drug Des Devel Ther; 2019; 13():539-553. PubMed ID: 30787595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
    Ushijima K; Kamura T; Tamura K; Kuzuya K; Sugiyama T; Noda K; Ochiai K
    Int J Clin Oncol; 2013 Feb; 18(1):126-31. PubMed ID: 22127346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.